VolitionRX (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals. The company is also developing human diagnostic applications intended to support the early detection and management of cancer, as well as research applications related to neutrophil extracellular traps and other disease processes.

Founded in 2010, VolitionRx is headquartered in Singapore and conducts research and commercial activities through operations in the United States and Europe. Its business has included collaborations with diagnostic laboratories, pharmaceutical companies, academic institutions and veterinary organizations as it works to advance and commercialize its nucleosome-based testing platforms.

Key Stats

• Today's Range: $0.23 to $0.24
• 50-Day Range: $0.23 to $0.88
• 52-Week Range: $0.23 to $13.40
• Volume: 200,302 shs
• Average Volume: 3.11 million shs
• Market Capitalization: $3.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

VolitionRX Stock Analysis - MarketRank™

VolitionRX scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

VolitionRX has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

VolitionRX has a consensus price target of $28.00, representing about 11,917.2% upside from its current price of $0.23.

Amount of Analyst Coverage

VolitionRX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRX is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRX is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.91% of the float of VolitionRX has been sold short.

Short Interest Ratio / Days to Cover

VolitionRX has a short interest ratio ("days to cover") of 0.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VolitionRX has recently decreased by 54.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRX does not currently pay a dividend.

Dividend Growth

VolitionRX does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for VolitionRX this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added VolitionRX to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VolitionRX insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.90% of the stock of VolitionRX is held by insiders.

Percentage Held by Institutions

8.09% of the stock of VolitionRX is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:VNRX
• Previous Symbol: NYSEMKT:VNRX
• CIK: 93314
• Web: www.volition.com
• Phone: (646) 650-1351
• Fax: 65 32 8172 5651
• Employees: 75
• Year Founded: N/A

Price Target and Rating

• Average Price Target for VolitionRX: $28.00
• High Price Target: $60.00
• Low Price Target: $4.00
• Potential Upside/Downside: +11,865.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.36 million
• Net Margins: -1,043.12%
• Pretax Margin: -1,046.83%
• Return on Equity: N/A
• Return on Assets: -303.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $1.73 million
• Price / Sales: 1.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.30) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 13,650,000
• Free Float: 12,707,000
• Market Cap: $3.19 million
• Optionable: Not Optionable
• Beta: 1.17